Text Size

The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01180907
First received: August 11, 2010
Last updated: July 27, 2012
Last verified: July 2012
History of Changes
  Purpose

The purpose of the study is to determine whether positron emission tomography using the new imaging agent 18F-FAC can be used for imaging cancer and/or inflammation.


Condition
Cancer
Inflammation

Study Type: Observational
Official Title: The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases: A Pilot Study

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by Jonsson Comprehensive Cancer Center:

Enrollment: 10
Study Start Date: November 2007
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
patients with cancer
patients with autoimmune diseases
healthy subjects

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

patients with cancer, autoimmune diseases and healthy subjects

Criteria

Inclusion Criteria:

  • > 18 years of age
  • women of childbearing potential will undergo a pregnancy test free of charge
  • patients with cancer or autoimmune diseases or healthy subjects
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01180907

Locations
United States, California
UCLA
Los Angeles, California, United States, 90095
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
Investigators
Principal Investigator: Christiaan Schiepers, M.D. Ph.D University of California, Los Angeles
  More Information

No publications provided

Responsible Party: Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT01180907     History of Changes
Other Study ID Numbers: 07-07-071, DE-PS02-08ER-08-01, CIRMNo. RT1-01126-1, 10-000269
Study First Received: August 11, 2010
Last Updated: July 27, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Jonsson Comprehensive Cancer Center:
18F-FAC
imaging
cancer
inflammation
PET

Additional relevant MeSH terms:
Inflammation
Pathologic Processes

ClinicalTrials.gov processed this record on May 23, 2013